U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Pseudohypoparathyroidism type II(PHP2)

MedGen UID:
444371
Concept ID:
C2932717
Disease or Syndrome
Synonyms: PHP II; PHP2; Pseudohypoparathyroidism type 2
SNOMED CT: Pseudohypoparathyroidism type 2 (42183005); Pseudohypoparathyroidism type II (42183005)
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
Concept ID:
CN307044
Finding
Source: Orphanet
clinical entity without genetic inheritance.
 
Monarch Initiative: MONDO:0008749
OMIM®: 203330
Orphanet: ORPHA94090

Definition

Pseudohypoparathyroidism (PHP) is a term applied to a heterogeneous group of disorders whose common feature is resistance to parathyroid hormone (PTH; 168450). PHP type II is characterized by a normal cAMP response to PTH infusion, but a deficient phosphaturic response, indicating a defect distal to cAMP generation in renal cells. The clinical features of Albright hereditary osteodystrophy (AHO; see 103580) are not present in PHP II (Mantovani and Spada, 2006). For a general phenotypic description, classification, and a discussion of molecular genetics of pseudohypoparathyroidism, see PHP1A (103580). [from OMIM]

Clinical features

From HPO
Hypocalcemia
MedGen UID:
5705
Concept ID:
C0020598
Disease or Syndrome
An abnormally decreased calcium concentration in the blood.
Hyperphosphatemia
MedGen UID:
39326
Concept ID:
C0085681
Disease or Syndrome
An abnormally increased phosphate concentration in the blood.
Elevated circulating parathyroid hormone level
MedGen UID:
167805
Concept ID:
C0857973
Finding
An abnormal increased concentration of parathyroid hormone.
Pseudohypoparathyroidism
MedGen UID:
46178
Concept ID:
C0033806
Disease or Syndrome
Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.

Recent clinical studies

Etiology

Saito H, Saito T
Horm Metab Res 1988 Nov;20(11):725. doi: 10.1055/s-2007-1010930. PMID: 2850988
Rao DS, Parfitt AM, Kleerekoper M, Pumo BS, Frame B
J Clin Endocrinol Metab 1985 Aug;61(2):285-90. doi: 10.1210/jcem-61-2-285. PMID: 2989317

Diagnosis

Murakami T, Nambu T, Morimoto Y, Matsuda Y, Matsuo K, Yonemitsu S, Muro S, Oki S
Intern Med 2014;53(7):743-7. Epub 2012 Mar 1 doi: 10.2169/internalmedicine.53.1617. PMID: 24694489
Srivastava T, Alon US
Clin Pediatr (Phila) 2002 May;41(4):263-8. doi: 10.1177/000992280204100411. PMID: 12041724
Saito H, Saito M, Saito K, Terauchi A, Kobayashi T, Tominaga T, Hosoi E, Senoo M, Saito K, Saito T
Am J Med Sci 1989 Apr;297(4):247-50. doi: 10.1097/00000441-198904000-00010. PMID: 2539718
Rao DS, Parfitt AM, Kleerekoper M, Pumo BS, Frame B
J Clin Endocrinol Metab 1985 Aug;61(2):285-90. doi: 10.1210/jcem-61-2-285. PMID: 2989317
Windeck R, Menken U, Benker G, Reinwein D
Clin Endocrinol (Oxf) 1981 Jul;15(1):57-63. doi: 10.1111/j.1365-2265.1981.tb02748.x. PMID: 7307284

Therapy

Mano T, Uchimura K, Hayashi R, Kobahashi T, Fujiwara K, Makino M, Kakizawa H, Nagata M, Nakai A, Wada M, Nagasaka A, Itoh M
Horm Metab Res 1999 Nov;31(11):602-5. doi: 10.1055/s-2007-978804. PMID: 10598827
Patel ZM, Ambani LM, Shah P, Sheth AR, Merchant SM
Indian Pediatr 1981 Nov;18(11):828-32. PMID: 6281182
Matsuda I, Takekoshi Y, Tanaka M, Matsuura N, Nagai B, Seino Y
Eur J Pediatr 1979;132(4):303-8. doi: 10.1007/BF00496854. PMID: 230052
Rodriguez HJ, Villarreal H Jr, Klahr S, Slatopolsky E
J Clin Endocrinol Metab 1974 Oct;39(4):693-701. doi: 10.1210/jcem-39-4-693. PMID: 4370302
Drezner M, Neelon FA, Lebovitz HE
N Engl J Med 1973 Nov 15;289(20):1056-60. doi: 10.1056/NEJM197311152892003. PMID: 4355058

Clinical prediction guides

Saito H, Saito M, Saito K, Terauchi A, Kobayashi T, Tominaga T, Hosoi E, Senoo M, Saito K, Saito T
Am J Med Sci 1989 Apr;297(4):247-50. doi: 10.1097/00000441-198904000-00010. PMID: 2539718
Yamada K, Tamura Y, Tomioka H, Kumagai A, Yoshida S
J Clin Endocrinol Metab 1984 Feb;58(2):339-43. doi: 10.1210/jcem-58-2-339. PMID: 6319447

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...